Phenytoin and Multidose Activated Charcoal

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phenytoin is a medicine used to treat seizures. If too much is taken, patients have ill effects including sleepiness, unsteady gait, and eye problems. The amount of drug in their system can be measured in their blood. Charcoal is a medicine that can absorb phenytoin. We want to see if giving multiple doses of charcoal will quicken the removal of phenytoin from the blood. This is theorized to occur as charcoal absorbs phenytoin from across the intestines and then is secreted in the stool. Patients will be selected to receive either charcoal in multiple doses or no charcoal and their serum levels will be drawn repeatedly to follow their level. The different groups will then be compared to see if multidose charcoal does indeed increase the elimination of phenytoin from the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fenfluramine for Adult Dravet Patients

NCT05560282

Dravet Syndrome Dravet Syndrome, Intractable

UNKNOWN PHASE3

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

NCT03350035

Status Epilepticus Convulsive Status EPILEPTICUS Non Convulsive Status Epilepticus +1 more

COMPLETED PHASE2

Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.

NCT01478035

Seizures Pneumococcal Meningitis

TERMINATED PHASE4

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753

Primary Generalized Epilepsy

COMPLETED PHASE3

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

NCT05605301

Epilepsy; Seizure

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

See above

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phenytoin Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Doses of Activated Charcoal

Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc

Group Type EXPERIMENTAL

Activated Charcoal

Intervention Type DRUG

50 grams by mouth every 4 hours until serum phenytoin level is less than 25.

Control

Will not receive activated charcoal. Serum levels will be followed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Activated Charcoal

50 grams by mouth every 4 hours until serum phenytoin level is less than 25.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Charcoal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Phenytoin level \> 30 mg/L

Exclusion Criteria

* Age \< 18
* Known allergy to Activated Charcoal
* Pregnant
* Inability to take PO drugs
* Non English speaking
* Inability to give consent
* Any prisoners

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No